Arvinas, Novartis in ARV-766 Prostate Cancer License Pact
By Colin Kellaher
Clinical-stage biotechnology company Arvinas has struck a licensing and asset-sale agreement potentially worth more than $1 billion with Swiss drugmaker Novartis.
Arvinas on Thursday said Novartis will make an upfront payment of $150 million in exchange for an exclusive license for the development and commercialization of ARV-766, the New Haven, Conn., company's second-generation Protac androgen receptor degrader for patients with prostate cancer, as well as the acquisition of its preclinical AR-V7 program.
Arvinas said it is also eligible to receive up to $1.01 billion in development, regulatory and commercial milestone payments, along with royalties on sales for ARV-766.
Arvinas said Novartis will be responsible for worldwide clinical development and commercialization of ARV-766, adding that it expects the partnership to accelerate and broaden the drug's development as a potential first-in-class treatment option for patients with prostate cancer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 11, 2024 07:42 ET (11:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations